GenomOncology to Present at Cleveland Clinic Medical Innovation Summit
News Oct 25, 2014
GenomOncology has announced that Manuel Glynias, the company’s President and CEO, will be presenting a corporate overview at the Cleveland Clinic’s 2014 Medical Innovation Summit to be held October 26-29 in Cleveland, IL.
The presentation will take place on Wednesday October 29 at 8:25 ET at the Cleveland Convention Center in Room 26. There will be a breakout for Q&A immediately following the presentation in Room 23.
GenomOncology is focused on enabling precision medicine by translating next generation sequencing data into actionable information for clinicians and researchers. The company’s proprietary technology platform, GO Clinical Workbench, streamlines the use of NGS data in conjunction with other analytic modalities and allows clinical laboratories to produce an actionable clinical report using the molecular profile of an individual patient’s tumor.
“I was pleased to be invited to participate in the Cleveland Clinic’s Medical Innovation Summit,” commented Manuel Glynias. “Translating the vast amounts of data from next-generation sequencing into useful information for clinical use is of the utmost importance. GenomOncology is dedicated to expanding the availability of this information to the industry and welcomes the opportunity to share ideas with conference attendees.”
Mr. Glynias is a serial entrepreneur with over 25 years of experience in bioinformatics. Immediately prior to GenomOncology, Manuel was a partner at Rosetta, a leading interactive marketing agency, where he helped develop big data solutions for ecommerce clients.
In the late 90’s, Manuel was the founder and CEO of NetGenics, a venture-backed provider of discovery informatics to the biopharmaceutical industry and academic research centers. He also developed a number of other commercial software platforms including MacGene, Gene Works, and Primer Express. Manuel has an AB in Biochemistry and Molecular Biology from Harvard College.
Organizations looking to benefit from the artificial intelligence (AI) revolution should be cautious about putting all their eggs in one basket, a study published in Nature Machine Intelligence has found. Researchers found that contrary to conventional wisdom, there can be no exact method for deciding whether a given problem may be successfully solved by machine learning tools.READ MORE